Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Galera Therapeutics
Galera Therapeutics
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech
Fri, 08/18/23 - 10:28 am
layoffs
Alaunos Therapeutics
BlueRock Therapeutics
Thermo Fisher
Bristol Myers Squibb
Atreca
Galera Therapeutics
Inovio
Salarius Pharmaceuticals
Karyopharm Therapeutics
Intergalatic Therapeutics
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
Yahoo/Zacks.com
Mon, 08/14/23 - 11:15 am
earnings
Legend Biotech
Kodiak Sciences
Galera Therapeutics
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis
BioSpace
Thu, 08/10/23 - 11:32 am
Galera Therapeutics
avasopasem manganese
layoffs
oral mucositis
head and neck cancer
FDA
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Galera earns key FDA designation for pancreatic cancer drug
Clinical Trials Arena
Fri, 05/19/23 - 11:29 am
Galera Therapeutics
pancreatic cancer
FDA
rucosopasem
orphan drugs
Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Bizjournals
Tue, 10/19/21 - 10:53 am
Galera Therapeutics
cancer
clinical trials
head and neck cancer
oral mucositis
GC4419
Galera claims positive update in pancreatic cancer but doesn't report p-values
Endpoints
Thu, 04/29/21 - 10:46 am
Galera Therapeutics
pancreatic cancer
GC4419
Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles
Endpoints
Mon, 10/14/19 - 09:58 am
IPOs
Galera Therapeutics
89Bio
Centogene
Clarus spearheads a big, $150M raise so Galera can flip the PhIII card on its new drug to treat radiation effects
Endpoints
Wed, 09/19/18 - 11:48 am
Galera Therapeutics